Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
CP+ Analysis

Rosemont's $56M Aytu bid shows buyers paying for growing launches, not pipelines

A $2.70-per-share tender for Aytu, with EXXUA at $4.9M of $14.8M quarterly revenue, sits among a run of small-cap deals and strategic reviews across the sector.

17 Nov 2026 · CompePharma editorial

What happened

Aytu BioPharma has agreed to be acquired by Rosemont Pharmaceuticals Holdings for about $56M. Rosemont will launch a cash tender offer at $2.70 per share. The announcement came with Aytu's first-quarter fiscal 2027 results: revenue of $14.8M, of which EXXUA contributed $4.9M, roughly one-third of the total.

The material does not give the tender's minimum-acceptance threshold, expected closing date, financing, or any premium to Aytu's prior share price. Those terms will determine how the deal is judged, and we do not speculate on them here.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Sources

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.

More CP+ AnalysisAll →